Gyros AB announced that Radix BioSolutions, a US-based contract research organization specializing in custom assay development, reagent manufacturing, and a provider of assay services, will integrate a Gyrolab xP workstation into its immunoassay development programs.
Kerry Oliver, CEO at Radix Biosolutions explained the reasoning behind the decision, “The Gyros platform enables us to develop immunoassays more rapidly than any other approaches currently available. At Radix we differentiate ourselves by fostering strong relationships with our customers by meeting project requirements and timelines, and always striving to exceed expectations. Our scientists provide the experience and capabilities in reagent definition and production, robust assay development and validation, and the regulatory compliance required during the development of a customer’s therapeutic. It is essential for us to leverage leading edge technology at each stage of a project in order to best fulfill the unique needs of each customer.”
“We are extremely pleased that Radix BioSolutions have recognized one of the key benefits of our immunoassay platform, namely rapid assay development. We also believe that their unique approach of making identified assay reagents commercially available will enable other Gyrolab xP workstation users working in GLP environments in the USA to procure quality controlled reagents from Radix for their own laboratory needs,” added Erik Walldén, CEO at Gyros.
Date: April 27, 2010